Imagine this. A young teenager, 17, years old, who is fully developed. Now imagine this, the same teenager has a fully developed extra set of limbs and a pelvis. That extra set of pair is attached with chest artery. But, how can this happen?

While it is extremely rare, and has a chance of less than one case occurring per 100,000 births. Such things do happen. This is called parasitic twin.

What Is A Parasitic Twin?

It is an extremely rare type of cojoined twin where a baby is born with an underdeveloped twin attached to its body. This condition is also known as vestigial twins. The condition is very closely related to conjoined twins, where babies are connected at birth and share organs. However, the main difference is that in conjoined twins, there are two developed babies, whereas in parasitic twins, only one is fully developed, other one is underdeveloped and non functional.

In such a case, the twin who is developed is medically known as the autositic or the dominant twin. The dominant twin is healthy in most aspect but may have extra tissue, organs, or limbs from the parasitic twin.

The parasitic twin may be attached with the dominant twin through several places. The common joints are at the head, torso, chest, pelvis, buttocks, or back. In these cases, the parasitic twin is not alive and they die either in the womb or during the childbirth.

Doctors Remove Parasitic Twin

Now, let's go back to the case we referred to, where a young teenager had an extra pair of limbs attached to chest. The teenager who has not been named is from Uttar Pradesh's Unnao neighbourhood, and was treated in AIIMS, Delhi. The team of doctors successfully removed the extra set of limbs from his body.

Dr Asuri Krishna, who led the team of specialist who surgically removed the extra limbs told the BBC that only 40 to 50 cases of parasitic twins have been documented in world medical literature, and in those cases, the surgery had been attempted on children. The doctor said that without much medical literature to guide them, the team of doctors depended on "intuition, skill and knowledge".

The doctor shared that the child had two fully formed legs, buttocks and external genitalia, which weighed around 15kg "protruding from his abdomen".

How Was The Surgery Performed?

The doctor shared that first they identified how interconnected the parasitic and host twins were. The doctors took scans and found that parasitic twin was attached to the teen's breastbone. The blood was being supplied from a vessel in his chest. However, "there wasn't much connection with other main organs like the liver or kidneys," said Dr Krishna. The team also found a large cyst in the teen's abdomen.

Then the surgery was performed in two stages. In the first stage, the parasitic twin was removed. Then the cystic mass was extracted from the surrounded area. The entire surgery was completed in two and a half hours and the team of doctors included radiologists, anaesthetists, and plastic surgeons.

The biggest challenge was when the teen's blood pressure dropped as 30 to 40% of his blood flowed to the parasitic twin, however, the doctors were prepared for it and they stabilized him.

Metformin is a safe and effective drug used by type 2 patients for the last six decades to control their blood sugar levels and improve the way the body handles insulin.

A recent study showed that metformin can also be crucial in reducing the risk of vision loss in people over the age of 50, known as age-related macular degeneration (AMD).

The observational study, published in the BMJ Open Ophthalmology, showed that metformin can cut down the cases of AMD by nearly 40 percent in people with Type 2 diabetes over five years.

“We have found a significant association between metformin use and a reduction in the incidence of intermediate AMD by 37 percent in people with diabetes over 5 years. Previous epidemiological studies of metformin and AMD have used secondary data on AMD,” said corresponding author Nicholas A. V. Beare, from the University of Liverpool, UK.

“Given metformin’s anti-aging therapeutic effects, the reduction in risk is plausible and warrants prospective clinical trials,” he added.

Also read: Metformin Controls Blood Sugar With Help From Brain Neurons, Finds Study

Metformin And AMD

While currently there is no specific treatment option for AMD — a common cause of blindness in high-income countries — scientists have shown interest in metformin as a candidate drug for treating AMD and reducing its progression.

It is because of metformin's antioxidant, anti-inflammatory, antiangiogenic, and antifibrotic effects. Metformin is also postulated to delay ageing and ageing-related diseases.

Previous research has also identified metformin as a potential treatment for all stages of AMD. Researchers also noted that the common diabetes drug is readily accessible and has a strong safety profile.

How Metformin Improves AMD

The BMJ study analyzed more than 2,500 participants aged 50 or above who attended retinopathy screening in 2011.

All participants had Type 2 diabetes and gradable fundus photographs — high-quality retinal images.

Individuals prescribed oral metformin had a 37 percent lower risk of intermediate AMD by five years. The results are consistent with known biological mechanisms, given metformin’s potential favourable effects on AMD progression, researchers reported, the researchers said.

The team, however, acknowledged limitations such as a lack of proper data regarding the dose, duration of prior use, or compliance with metformin use.

Further, there were only a relatively small number of participants developing advanced AMD – an inevitability in population-based studies. They urged for a clinical trail to prove metformin's potential in treating AMD.

Also read: World Sight Day: 10 Tips To Help Prevent Vision Loss In Elderly

What Is AMD?

Age-related macular degeneration (AMD) is a disease of the retina. It happens when a part of the retina called the macula is damaged. It results in the loss of sharp, straight-ahead vision.

The condition commonly affects adults over 50, and causes

• blurry vision,
• dark spots,
• distorted straight lines.

While AMD rarely causes total blindness but affects central vision, making reading and driving difficult. It is of two types:

• Dry Age-Related Macular Degeneration
• Wet Age-Related Macular Degeneration

Harry Potter star Daniel Radcliffe has quit smoking after 20 long years. The reason: his two–year–old son with girlfriend Erin Darke.

Speaking to media outlet Vulture, the 36-year-old English actor shared that after becoming a father, he was inspired by intrusive thoughts about his mortality, which enabled him to quit the deadly habit after two decades.

"I smoked for 20 years pretty heavily, and I was never even thinking about quitting, and then shortly after having my son, the intrusive thoughts of my own death really helped as an incentive to quit," Radcliffe was quoted as saying.

Radcliffe also shared how a book -- The Easy Way to Quit Smoking, by Alan Carr -- helped him decide to quit smoking.

"It may not work for everybody, but it really worked for me," noted the star, currently starring in the Broadway play Every Brilliant Thing.

Earlier this month, the actor spoke with WSJ Magazine and shared that from being on “cigarettes all day”, he's transformed into a fitness freak.

How Does Smoking Affect Our Body?

Smoking can affect all organs in our body. While lung cancer and tuberculosis are the most prominent ones, smoking can seriously increase the risk of several chronic diseases. These include:

• Heart Disease
• Asthma
• Reproductive Health
• Vision Loss
• Chronic Obstructive Pulmonary Disease
• Cancers of the liver, stomach, and colon.

While quitting tobacco is important, it is a difficult task, with some people finding it harder to quit than others. It may be important to seek help quitting.

Also read: Cigarettes And The Female Body: The Hormonal Toll We Don’t Talk About

What Happens When You Stop Smoking?

• In just 20 minutes of stopping, your blood pressure and heart rate begin to normalize.
• Within a few weeks, your lung function improves.
• Over time, the risk of heart disease and cancer also decreases dramatically.

These strategies have shown varying levels of success in aiding smokers to quit permanently. In addition, alternative methods like e-cigarettes and mindfulness-based techniques have gained traction in helping reduce smoking addiction.

Science-backed Methods To Help You Quit Smoking

Behavioral Support

Quitting smoking isn’t just about resisting cravings. Often, behavioral support through counseling or therapy is crucial for tackling the psychological aspects of addiction. Behavioral therapy involves working with a trained professional to identify triggers, develop coping strategies, and create a tailored quit plan. Research shows that combining counseling with other quit methods can significantly increase success rates.

Prescription Medications

Some medications, such as varenicline (Chantix) and bupropion (Zyban), have been shown to help people quit smoking by reducing cravings and withdrawal symptoms. Experts suggest that varenicline works by blocking the effects of nicotine in the brain, while bupropion is an antidepressant that helps manage withdrawal symptoms. Both medications are generally more effective when combined with behavioral therapy.

Nicotine Replacement Therapy (NRT)

Nicotine replacement products, such as nicotine patches, gums, lozenges, and nasal sprays, deliver controlled amounts of nicotine to ease withdrawal symptoms. According to experts at Harvard Health, NRT can double the chances of quitting by alleviating physical cravings while the person works on overcoming the psychological addiction.

About 10.6 percent –15 percent of India's population suffers from some form of mental health conditions, with 15 percent of the adult population also requiring active intervention.

To enable researchers to gather as well as systematically document data on patients with major forms of mental illness, neuroscientists in India have developed CALM-Brain — a digital repository of data on brain structure and function from a range of psychiatric disorders.

CALM-Brain contains data from over 2,000 participants from 900 families across the country.

CALM-Brain will help clinicians and researchers

• to understand the onset of neuropsychiatric disease
• check progression
• decode underlying biological changes
• provide better diagnosis
• plan personalized treatments for patients.

“CALM-Brain was conceived as a method to assemble data from multiple scales of analysis of brain structure and function on a single platform. We believe that the application of modern methods of data analysis to this dataset will help bridge the gap between these scales of analysis,” said Prof. Raghu Padinjat, CBM co-ordinator at CBM-NCBS, in a statement.

Also read: World Happiness Report 2026 Flags Social Media Harms On Adolescents' Mental Well-being

What Is CALM-Brain?

CALM-Brain is the result of collaborative efforts of researchers at the Rohini Nilekani Centre for Brain and Mind (CBM) — a partnership between the National Institute of Mental Health and Neuro Sciences (NIMHANS) and the National Centre for Biological Sciences (NCBS) - TIFR.

CALM-Brain is India’s first-of-its-kind repository of clinical, neuroimaging, behavioral, genetic, and other datasets on disorders such as:

• addiction,
• bipolar disorder,
• dementia,
• obsessive compulsive disorder (OCD)
• schizophrenia.

• Functional Magnetic Resonance Imaging (fMRI)
• Near Infrared Spectroscopy (NIRS)
• electroencephalogram (EEG)
• observations of cognition
• eye-tracking
• genetic analyses of blood samples
• clinical assessments.

The dataset is also linked to a biorepository of stem cells, which can be used to perform biological research in psychiatry to understand the origins of such severe mental illnesses.

“The primary goals of the project are to identify biological markers of severe psychiatric illnesses, which cut across traditional diagnostic frameworks. In addition, we will try to identify fundamental biological mechanisms of the disease and medication response,” said Prof. Y.C. Janardhan Reddy, CBM coordinator at CBM-NIMHANS.

Burden Of Mental Illnesses In India

Mental wellness is a major health and economic concern in India. The World Health Organization (WHO) estimates India’s economic loss due to mental health conditions to be USD 1.03 trillion (2012-2030).

Recently, health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.

"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.

They added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)" among citizens.

To address the rising burden, the government aims to launch NIMHANS-2 — first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27 — to deliver specialized care for mental health and neurological disorders in north India.

"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," FM Sitharaman said.